Stockwatch: The Desert After The Bubble
This article was originally published in Scrip
Executive Summary
After the controversies surrounding drug pricing and specialty pharmacy channel stuffing it is no wonder that we are in the lackluster period after the bursting of the 2015 biotech bubble. Traditionally the aftermath of burst stock market bubbles can be associated with years in the investment wilderness, where generalist investors mostly avoid the sector.